Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network

MLA

Ghesquieres, Herve, et al. “Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a ‘Proof of Concept’ Phase II Study of the French LOC Network.” Blood, vol. 128, no. 22, Jan. 2016, p. 785. EBSCOhost, https://doi.org/10.1182/blood.V128.22.785.785.

APA

Ghesquieres, H., Houillier, C., Chinot, O., Choquet, S., Molucon-Chabrot, C., Beauchene, P., Gressin, R., Morschhauser, F., Schmitt, A., Gyan, E., Hoang-Xuan, K., Nicolas-Virelizier, E., Chevrier, M., Savignoni, A., Turbiez, I., Veillas, F., Soumelis, V., & Soussain, C. (2016). Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a “Proof of Concept” Phase II Study of the French LOC Network. Blood, 128(22), 785. https://doi.org/10.1182/blood.V128.22.785.785

Chicago

Ghesquieres, Herve, Caroline Houillier, Olivier Chinot, Sylvain Choquet, Cecile Molucon-Chabrot, Patrick Beauchene, Remy Gressin, et al. 2016. “Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a ‘Proof of Concept’ Phase II Study of the French LOC Network.” Blood 128 (22): 785. doi:10.1182/blood.V128.22.785.785.